Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress

PR Newswire August 4, 2015

Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma

PR Newswire July 20, 2015

Delcath Announces Pricing Of Public Offering

PR Newswire July 16, 2015

Delcath Announces Acceptance Of Abstracts For Presentation At The Cardiovascular And Interventional Radiology Society Annual Meeting

PR Newswire June 9, 2015

Delcath to Webcast Management's Presentation at Annual Meeting of Shareholders on June 10, 2015

PR Newswire June 5, 2015

Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015

PR Newswire May 29, 2015

Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer Patients

PR Newswire May 27, 2015

Delcath Names Dr. Jennifer Simpson President And CEO

PR Newswire May 26, 2015

ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment

PR Newswire May 21, 2015

Delcath Reports 2015 First Quarter Financial Results

PR Newswire May 6, 2015

Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma

PR Newswire April 21, 2015

Delcath to present at Needham & Company's 14th Annual Healthcare Conference

PR Newswire April 10, 2015

Delcath Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program

PR Newswire April 7, 2015

Delcath Activates Prospective Registry In Europe

PR Newswire April 2, 2015

Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting

PR Newswire March 27, 2015

Delcath Reports 2014 Fourth Quarter And Full Year Financial Results

PR Newswire March 10, 2015

Delcath Announces Melphalan/HDS Poster Presentation To Be Presented At The Society Of Surgical Oncology Annual Meeting

PR Newswire March 9, 2015

Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal

PR Newswire March 3, 2015

Delcath To Present At The 27th Annual Roth Conference

PR Newswire March 2, 2015

Delcath Prices $2.8 Million Public Offering of Common Stock and Warrants

PR Newswire February 11, 2015
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested